Message from the Guest Editor

Dear Colleagues,

Advancement in pancreatic cancer management has been dishearteningly slow. In the age of molecularly-targeted drugs and immunotherapy, the best treatment option for advanced and metastatic patients, which is the majority, remain combinations of cytotoxic drugs. For those fortunate enough to undergo curative pancreatectomy, cancer recurrence continues to be a real and significant concern. This Special Issue will discuss recent development in our understanding of the biology and genomic characteristics, early detection research, innovations in the treatment of localized disease and therapeutics targeting novel targets in pancreatic cancer.

Prof. Dr. Wen Wee Ma
Guest Editor
Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 18 days after submission; acceptance to publication is undertaken in 4.14 days (median values for papers published in the first six months of 2018).

Contact us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI